Mitochondrial Health

Archival Status

The Mitochondrial Health protocol pairs SS-31 (Elamipretide) and MOTS-c to protect and restore mitochondrial function from two complementary angles: cardiolipin membrane stabilization (SS-31) and mitochondrial retrograde nuclear signaling (MOTS-c). SS-31 (Szeto-Schiller Peptide 31, also known as Elamipretide or MTP-131) is a cell-permeable tetrapeptide that selectively concentrates in the inner mitochondrial membrane (IMM) through electrostatic and hydrophobic interaction with cardiolipin — a phospholipid unique to the IMM that is critical for electron transport chain (ETC) complex organization and cristae architecture. In aging, disease, and ischemic stress, cardiolipin oxidation and remodeling disrupt ETC supercomplex assembly, reducing ATP synthesis efficiency and increasing reactive oxygen species (ROS) production. SS-31 stabilizes cardiolipin, restores ETC supercomplex formation, and dramatically reduces mitochondrial ROS production without directly scavenging free radicals — addressing the mechanistic root cause rather than the downstream oxidative damage. Clinical trials (PROGRESS-HF, HALOS) have advanced SS-31 into Phase 2 cardiac research with encouraging safety profiles. MOTS-c is encoded within the mitochondrial 12S rRNA and functions as a retrograde mitochondrial signal — communicating mitochondrial metabolic status to the nucleus to coordinate nuclear gene expression responses. It activates AMPK, promotes mitochondrial biogenesis through PGC-1alpha, improves insulin sensitivity, and has demonstrated protective effects against metabolic stress in multiple rodent models. Its circulating levels decline with age and in insulin-resistant states, suggesting exogenous replacement could help maintain mitochondrial signaling capacity across aging. The mechanistic synergy is layered: SS-31 maintains the structural integrity of the inner mitochondrial membrane and ETC function, while MOTS-c ensures appropriate nuclear responses to mitochondrial status and drives ongoing biogenesis. Together, they address both the preservation of existing mitochondria (SS-31) and the generation and quality control of new ones (MOTS-c). Research applications include: age-related mitochondrial decline, heart failure, metabolic syndrome, ischemia-reperfusion injury models, and neurodegenerative disease research.